Longer duration of B cell depletion is associated with better outcome

Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids

(2013) Marie B Condon et al.   ANNALS OF THE RHEUMATIC DISEASES

Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus

(2013) V. Reddy et al.   RHEUMATOLOGY

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

B cell elimination in systemic lupus erythematosus

(2012) João Furtado et al.   CLINICAL IMMUNOLOGY

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen

(2011) A. N. Ezeonyeji et al.   RHEUMATOLOGY

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids

(2009) R. Pepper et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

(2008) D Albert et al.   ANNALS OF THE RHEUMATIC DISEASES